Abstract
Objective: To appraise multiple systematic reviews on the same clinical topic, focusing on predictors and correlates of quality of reporting of meta-analysis (QUOROM) scores. Design: Case study. Setting: Reviews providing at least individual quantitative estimates on role of acetylcysteine in the prevention of contrast associated nephropathy. Data sources: PubMed, the database of abstracts of reviews of effects, and the Cochrane database of systematic reviews (updated March 2005). Main outcome measures: Funding, compliance with the QUOROM checklist, scores on the Oxman and Guyatt quality index, and authors' recommendations. Results: 10 systematic reviews, published August 2003 to March 2005, were included. Nine pooled events despite heterogeneity and five recommended routine use of acetylcysteine, whereas the remaining studies called for further research. Compliance with the 18 items on the QUOROM checklist was relatively high (median 16, range 11 to 17), although shorter manuscripts had significantly lower scores (R = 0.73; P = 0.016). Reviewers who reported previous not for profit funding were more likely to score higher on the Oxman and Guyatt quality index. No association was found between QUOROM and Oxman and Guyatt scores (R = - 0.06; P = 0.86), mainly because of greater emphasis of the Oxman and Guyatt scores on the appraisal of bias in selection and validity assessment (inadequate in five reviews). Conclusions: Multiple systematic reviews on the same clinical topic varied in quality of reporting and recommendations. Longer manuscripts and previous not for profit funding were associated with higher quality.
| Original language | English |
|---|---|
| Pages (from-to) | 202-206 |
| Number of pages | 5 |
| Journal | British Medical Journal |
| Volume | 332 |
| Issue number | 7535 |
| DOIs | |
| Publication status | Published - Jan 28 2006 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy : Case study. / Biondi-Zoccai, Giuseppe G L; Lotrionte, Marzia; Abbate, Antonio; Testa, Luca; Remigi, Enrico; Burzotta, Francesco; Valgimigli, Marco; Romagnoli, Enrico; Crea, Filippo; Agostoni, Pierfrancesco.
In: British Medical Journal, Vol. 332, No. 7535, 28.01.2006, p. 202-206.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy
T2 - Case study
AU - Biondi-Zoccai, Giuseppe G L
AU - Lotrionte, Marzia
AU - Abbate, Antonio
AU - Testa, Luca
AU - Remigi, Enrico
AU - Burzotta, Francesco
AU - Valgimigli, Marco
AU - Romagnoli, Enrico
AU - Crea, Filippo
AU - Agostoni, Pierfrancesco
PY - 2006/1/28
Y1 - 2006/1/28
N2 - Objective: To appraise multiple systematic reviews on the same clinical topic, focusing on predictors and correlates of quality of reporting of meta-analysis (QUOROM) scores. Design: Case study. Setting: Reviews providing at least individual quantitative estimates on role of acetylcysteine in the prevention of contrast associated nephropathy. Data sources: PubMed, the database of abstracts of reviews of effects, and the Cochrane database of systematic reviews (updated March 2005). Main outcome measures: Funding, compliance with the QUOROM checklist, scores on the Oxman and Guyatt quality index, and authors' recommendations. Results: 10 systematic reviews, published August 2003 to March 2005, were included. Nine pooled events despite heterogeneity and five recommended routine use of acetylcysteine, whereas the remaining studies called for further research. Compliance with the 18 items on the QUOROM checklist was relatively high (median 16, range 11 to 17), although shorter manuscripts had significantly lower scores (R = 0.73; P = 0.016). Reviewers who reported previous not for profit funding were more likely to score higher on the Oxman and Guyatt quality index. No association was found between QUOROM and Oxman and Guyatt scores (R = - 0.06; P = 0.86), mainly because of greater emphasis of the Oxman and Guyatt scores on the appraisal of bias in selection and validity assessment (inadequate in five reviews). Conclusions: Multiple systematic reviews on the same clinical topic varied in quality of reporting and recommendations. Longer manuscripts and previous not for profit funding were associated with higher quality.
AB - Objective: To appraise multiple systematic reviews on the same clinical topic, focusing on predictors and correlates of quality of reporting of meta-analysis (QUOROM) scores. Design: Case study. Setting: Reviews providing at least individual quantitative estimates on role of acetylcysteine in the prevention of contrast associated nephropathy. Data sources: PubMed, the database of abstracts of reviews of effects, and the Cochrane database of systematic reviews (updated March 2005). Main outcome measures: Funding, compliance with the QUOROM checklist, scores on the Oxman and Guyatt quality index, and authors' recommendations. Results: 10 systematic reviews, published August 2003 to March 2005, were included. Nine pooled events despite heterogeneity and five recommended routine use of acetylcysteine, whereas the remaining studies called for further research. Compliance with the 18 items on the QUOROM checklist was relatively high (median 16, range 11 to 17), although shorter manuscripts had significantly lower scores (R = 0.73; P = 0.016). Reviewers who reported previous not for profit funding were more likely to score higher on the Oxman and Guyatt quality index. No association was found between QUOROM and Oxman and Guyatt scores (R = - 0.06; P = 0.86), mainly because of greater emphasis of the Oxman and Guyatt scores on the appraisal of bias in selection and validity assessment (inadequate in five reviews). Conclusions: Multiple systematic reviews on the same clinical topic varied in quality of reporting and recommendations. Longer manuscripts and previous not for profit funding were associated with higher quality.
UR - http://www.scopus.com/inward/record.url?scp=31644436390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31644436390&partnerID=8YFLogxK
U2 - 10.1136/bmj.38693.516782.7C
DO - 10.1136/bmj.38693.516782.7C
M3 - Article
C2 - 16415336
AN - SCOPUS:31644436390
VL - 332
SP - 202
EP - 206
JO - British Medical Journal
JF - British Medical Journal
SN - 0959-8146
IS - 7535
ER -